EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of Major Lipid-Lowering Drug Targets on Circulating Fatty Acids: A Mendelian Randomization Study

C. Mary Schooling, Zhu Liduzi Jiesisibieke

Genes · 25.10.2026 · 17 (11) · 1335

DOI: 10.3390/genes17111335 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, online erschienen am 25.10.2026. Verfasst von C. Mary Schooling und 1 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The effects of major lipid-lowering therapies on circulating fatty-acid profiles are not fully characterized. We used Mendelian randomization (MR) to examine the effects of major lipid-lowering drug targets, proven to reduce CVD risk, on circulating fatty acids.

Methods

We conducted a drug-target MR analysis assessing genetically proxied statins (HMGCR), PCSK9 inhibitors and ezetimibe (NPC1L1) on circulating fatty acids. Each drug target was proxied by variants associated with low-density lipoprotein cholesterol (LDL-c) within/near the respective gene. Summary associations with fatty acids were obtained from the largest available genome-wide association study comprising 7816 to 115,006 individuals of European descent. One functionally relevant genetic variant was used to proxy each drug target, so the Wald ratio was used to obtain causal estimates.

Results

Genetically proxied inhibition of HMGCR, PCSK9, and NPC1L1 all reduced LDL-c, consistent with the expected drug effects. All three most clearly and consistently reduced polyunsaturated fatty acids, omega-6 and linoleic acid (LA) (e.g., statin on LA: −0.69, 95% confidence intervals: −0.80 to −0.58). In contrast, these genetically proxied lipid-lowering therapies had little effect on total omega-3s, eicosapentaenoic acid or arachidonate.

Conclusions

Genetically proxied lipid-lowering therapies that protect against CVD were associated with lower circulating LA. The biological significance of this association and its relation to dietary intake and cardiovascular benefit remain uncertain.

Zitieren

APA

Schooling, C. M., & Jiesisibieke, Z. L. (2026). Effects of Major Lipid-Lowering Drug Targets on Circulating Fatty Acids: A Mendelian Randomization Study. Genes, 17(11), 1335. https://doi.org/10.3390/genes17111335

Vancouver

Schooling CM, Jiesisibieke ZL. Effects of Major Lipid-Lowering Drug Targets on Circulating Fatty Acids: A Mendelian Randomization Study. Genes. 2026;17(11):1335. doi:10.3390/genes17111335

BibTeX
@article{Schooling2026,
  author = {Schooling, C. Mary and Jiesisibieke, Zhu Liduzi},
  title = {Effects of Major Lipid-Lowering Drug Targets on Circulating Fatty Acids: A Mendelian Randomization Study},
  journal = {Genes},
  year = {2026},
  volume = {17},
  number = {11},
  pages = {1335},
  doi = {10.3390/genes17111335}
}
Kostenlos starten →